WEBULL
WebtradeDownload

Ypsomed Holding (SWX:YPSN) Expands In North Carolina, Is The Growth Story Still Undervalued?

Simply Wall St · 1d ago

Why Ypsomed Holding’s Expansion Matters Now

Ypsomed Holding (SWX:YPSN) is building its first US advanced manufacturing facility in Holly Springs, North Carolina, aiming to increase capacity for self injection systems as global demand for self care solutions grows.

Recent trading has been choppy for Ypsomed Holding. The share price is up 6.83% year to date and shows a 1.15% 90 day share price return, yet the 30 day share price return is down 13.48% and the 1 year total shareholder return is down 2.28%. The 3 and 5 year total shareholder returns of 36.01% and 134.09% suggest longer term holders have still seen solid compounding despite the recent pullback, which may reflect investors reassessing growth potential and execution risk around expansions such as the new US facility.

Compare Ypsomed Holding’s expansion story with other health-focused manufacturers by scanning the hand-picked list of solid balance sheet and fundamentals (198 results) for potential peers with similar fundamental strength.

Bulls argue Ypsomed Holding’s US expansion justifies paying up for growth, while bears point to the recent share price drop and execution risk. Which story do the current valuation tools support next?

Most Popular Narrative: 9.7% Undervalued

At a last close of CHF350.40 versus a narrative fair value of CHF387.83, Ypsomed Holding is framed as modestly undervalued, with that gap tied directly to how well the US and China build outs convert into future cash flows.

The substantial investment in capacity expansion, including the construction of new factories and increased production capacity, aligns with anticipated growth in demand for delivery systems, potentially leading to future revenue growth (expected impact on revenue).
Ypsomed's robust pipeline of 200 ongoing projects and strategic partnerships in the GLP-1 space, with over 40 deals, positions the company for sustained long-term revenue growth as new drug delivery systems enter the market (expected impact on revenue).

See why 5 investors see Ypsomed Holding as 10% undervalued.

Result: Fair Value of CHF387.83 (UNDERVALUED)

Still, the narrative can crack if Ypsomed Holding’s heavy capacity build strains cash flows or if key GLP 1 and Cagrisema linked projects underdeliver.

Find out about the key risks to this Ypsomed Holding narrative.

Next Steps

Mixed signals around Ypsomed Holding can pull sentiment in either direction, so move quickly, review the full risk and reward data, and judge it on your own terms with 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ypsomed Holding?

If you stop with Ypsomed Holding, you could miss other opportunities that match your style, so widen your view and pressure test your next move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.